Champions Oncology's basic earnings per share (Basic EPS) for the
three
months ended in Jan. 2025 was $0.33.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2025 was $0.47.
Champions Oncology's EPS without NRI for the
three
months ended in Jan. 2025 was $0.36.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2025 was 0.49.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Champions Oncology's highest 3-Year average EPS without NRI Growth Rate was 61.30% per year. The lowest was -188.40% per year. And the median was 3.90% per year.
Champions Oncology EPS (Basic) Historical Data
The historical data trend for Champions Oncology's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Champions Oncology's Basic EPS for the fiscal year that ended in Apr. 2024 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (NAS:CSBR) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Champions Oncology EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Champions Oncology's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your 